MLYS MINERALYS THERAPEUTICS INC

Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET

Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET

Luke Laffin, MD, Cleveland Clinic, to discuss latest data from the pivotal Advance-HTN and Launch-HTN clinical trials and the potential of lorundrostat in hypertension

RADNOR, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will host a conference call and webinar featuring Dr. Luke Laffin of the Cleveland Clinic, who will discuss the latest results from the pivotal Advance-HTN and Launch-HTN clinical trials, and offer his perspective on the unmet medical need in uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), and the potential of lorundsrostat to change the current treatment paradigm.



Tuesday, April 1st @ 8:00 a.m. ET
Domestic:  1-877-704-4453 
International:   1-201-389-0920
Webcast:  



A live webcast of the conference call may also be found on the “” page in the Investor Relations section of the Mineralys Therapeutics website.

About Mineralys Therapeutics

Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions affected by dysregulated aldosterone, including hypertension, CKD and OSA. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit . Follow Mineralys on and .

Contact:

Investor Relations

Media Relations

Tom Weible

Elixir Health Public Relations

Phone: (1) 515-707-9678

Email:



EN
25/03/2025

Underlying

MLYSMINERALYS THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MINERALYS THERAPEUTICS INC

 PRESS RELEASE
Free
MLYS MINERALYS THERA...

Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from ...

Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET Luke Laffin, MD, Cleveland Clinic, to discuss latest data from the pivotal Advance-HTN and Launch-HTN clinical trials and the potential of lorundrostat in hypertension RADNOR, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driv...

21h / 20m 1 EN
Jonathan Moreland
  • Jonathan Moreland
Free Trial
TTSH Tile Shop Holdi...
STAA Staar Surgical ... ... (+54)

InsiderInsights Weekly Report: March 22, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

TTSH TILE SHOP HOLDINGS INC.
STAA STAAR SURGICAL CO.
SRE SEMPRA ENERGY
PSEC PROSPECT CAPITAL CORPORATION
ORRF ORRSTOWN FINANCIAL SERVICES INC.
OPK OPKO HEALTH INC.
OMCL OMNICELL INC.
MG MISTRAS GROUP
MEI METHODE ELECTRONICS INC.
HSC HARSCO CORPORATION
GOGO GOGO INC.
FRPT FRESHPET INC
AHH ARMADA HOFFLER PROPERTIES INC.
ADBE ADOBE INC.
OPRX OPTIMIZERX CORP
QRHC QUEST RESOURCE HOLDING
HRTG HERITAGE INSURANCE HOLDINGS INC.
CULP CULP INC.
CMCO COLUMBUS MCKINNON CORPORATION
MAC MACERICH COMPANY
PETS PETMED EXPRESS INC.
TREE LENDINGTREE INC.
ECC EAGLE POINT CREDIT CO INC
GCBC GREENE COUNTY BANCORP INC.
HI HILLENBRAND INC.
FLWS 1-800-FLOWERS.COM CL A
MX MAGNACHIP SEMICONDUCTOR CORP.
TCPC BLACKROCK TCP CAPITAL CORP.
BV BRIGHTVIEW HOLDINGS
HFFG HF FOODS GROUP INC
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
FTHM FATHOM HOLDINGS
CLVT CLARIVATE PLC
LYEL LYELL IMMUNOPHARMA INC
FLNC FLUENCE ENERGY INC
HD HOME DEPOT
BTMD INC.
ECAT HAYMAKER ACQUISITION CORP III
BUKS BLACKROCK ESG CAP ALLOCATION TR
ONL BUTLER NATIONAL CORP
MLYS ORION OFFICE REIT INC
WEST MINERALYS THERAPEUTICS INC
SBGI WESTROCK COFFEE COMPANY LLC
DK SINCLAIR INC
CVI DELEK US HOLDINGS
SRBK INC.
GUTS CVR ENERGY
ADVM INC.
SUNS SR BANCORP INC
AFCG FRACTYL HEALTH INC
ADVERUM BIOTECHNOLOGIES INC.
SUNRISE REALTY TRUST
AFC GAMMA
INC.
03/23/25 March 23, 2025 1 EN
 PRESS RELEASE
Free
MLYS MINERALYS THERA...

Mineralys Therapeutics Announces Closing of Underwriters’ Option to Pu...

Mineralys Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock RADNOR, Pa., March 18, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today the closing of the sale of an additional 1,944,444 shares of its common stock at a public offering price of $13.50 per share p...

March 18, 2025 1 EN
Jonathan Moreland
  • Jonathan Moreland
Free Trial
SRE SEMPRA ENERGY
PSEC Prospect Capita... ... (+33)

InsiderInsights.com Daily Ratings Report: March 17, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

SRE SEMPRA ENERGY
PSEC PROSPECT CAPITAL CORPORATION
OPK OPKO HEALTH INC.
FRPT FRESHPET INC
HRTG HERITAGE INSURANCE HOLDINGS INC.
CULP CULP INC.
MAC MACERICH COMPANY
ORN ORION GROUP HOLDINGS
TREE LENDINGTREE INC.
NKSH NATIONAL BANKSHARES INC.
FLWS 1-800-FLOWERS.COM CL A
MX MAGNACHIP SEMICONDUCTOR CORP.
TCPC BLACKROCK TCP CAPITAL CORP.
XAIR BEYOND AIR
CMPR CIMPRESS PLC
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
PRDO PERDOCEO EDUCATION CORP
FET FORUM ENERGY TECHNOLOGIES
SEAT VIVID SEATS INC.
FLNC FLUENCE ENERGY INC
BTMD HAYMAKER ACQUISITION CORP III
ECAT BLACKROCK ESG CAP ALLOCATION TR
ONL ORION OFFICE REIT INC
MLYS MINERALYS THERAPEUTICS INC
DK DELEK US HOLDINGS
CVI INC.
CUBA CVR ENERGY
SUNS INC.
AFCG THE HERZFELD CARIBBEAN BASIN FUND
INC.
SUNRISE REALTY TRUST
AFC GAMMA
INC.
03/18/25 March 18, 2025 1 EN
 PRESS RELEASE
Free
MLYS MINERALYS THERA...

Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Tri...

Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology’s Annual Scientific Session & Expo RADNOR, Pa., March 17, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea and other diseases driven by dysregulated aldosterone, today announced that data from the Phase 2 A...

March 17, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch